Illumina (ILMN) : Windward Capital Management Co Ca reduced its stake in Illumina by 7.14% during the most recent quarter end. The investment management company now holds a total of 23,934 shares of Illumina which is valued at $3,302,892 after selling 1,841 shares in Illumina , the firm said in a disclosure report filed with the SEC on Oct 14, 2016.Illumina makes up approximately 0.62% of Windward Capital Management Co Ca’s portfolio.
Other Hedge Funds, Including , Integrated Investment Consultants reduced its stake in ILMN by selling 124 shares or 20.74% in the most recent quarter. The Hedge Fund company now holds 474 shares of ILMN which is valued at $65,412. Illumina makes up approx 0.03% of Integrated Investment Consultants’s portfolio.Msi Financial Services Inc reduced its stake in ILMN by selling 134 shares or 15.24% in the most recent quarter. The Hedge Fund company now holds 745 shares of ILMN which is valued at $102,192.British Columbia Investment Management Corp reduced its stake in ILMN by selling 10,383 shares or 13.53% in the most recent quarter. The Hedge Fund company now holds 66,350 shares of ILMN which is valued at $9,221,987. Illumina makes up approx 0.09% of British Columbia Investment Management Corp’s portfolio. Patten Patten Inctn added ILMN to its portfolio by purchasing 1,160 company shares during the most recent quarter which is valued at $161,228. Illumina makes up approx 0.02% of Patten Patten Inctn’s portfolio.Telemus Capital boosted its stake in ILMN in the latest quarter, The investment management firm added 149 additional shares and now holds a total of 2,242 shares of Illumina which is valued at $417,393. Illumina makes up approx 0.05% of Telemus Capital’s portfolio.
Illumina opened for trading at $138.42 and hit $139.35 on the upside on Friday, eventually ending the session at $138, with a gain of 0.61% or 0.83 points. The heightened volatility saw the trading volume jump to 14,68,694 shares. Company has a market cap of $20,231 M.
On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Many Wall Street Analysts have commented on Illumina. Illumina was Downgraded by Citigroup to ” Neutral” on Oct 11, 2016. Shares were Reiterated by Cantor Fitzgerald on Oct 11, 2016 to “Hold” and Lowered the Price Target to $ 155 from a previous price target of $165 .Shares were Reiterated by Canaccord Genuity on Oct 11, 2016 to “Hold” and Lowered the Price Target to $ 136 from a previous price target of $165 .
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.